Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2006 Jun 28;12(2):147–156. doi: 10.1002/mrdd.20105

Childhood multiple sclerosis: A review

Amy Waldman 1,2, Erin O'Connor 2, Gihan Tennekoon 1,2,✉
PMCID: PMC7168360  PMID: 16807911

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS) that is increasingly recognized as a disease that affects children. Similar to adult‐onset MS, children present with visual and sensory complaints, as well as weakness, spasticity, and ataxia. A lumbar puncture can be helpful in diagnosing MS when CSF immunoglobulins and oligoclonal bands are present. White matter demyelinating lesions on MRI are required for the diagnosis; however, children typically have fewer lesions than adults. Many criteria have been proposed to diagnose MS that have been applied to children, mostly above 10 years of age. The recent revisions to the McDonald criteria allow for earlier diagnosis, such as after a clinically isolated event. However, children are more likely than adults to have monosymptomatic illnesses. None of the approved disease‐modifying therapies used in adult‐onset MS have been approved for pediatrics; however, a few studies have verified their safety and tolerability in children. Although children and adults with MS have similar neurological symptoms, laboratory (cerebrospinal fluid) data, and neuroimaging findings, the clinical course, pathogenesis, and treatment of childhood onset MS require further investigation. MRDD Research Reviews 2006;12:147–156. © 2006 Wiley‐Liss, Inc.

Keywords: multiple sclerosis, children, clinical features, pathogenesis, therapy

REFERENCES

  1. Aharoni R, Kayhan B, Eilam R, et al. 2003. Glatiramer acetate‐specific T cells in the brain express T helper 2/3 cytokines and brain‐derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100: 14157–14162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azoulay D, Vachapova V, Shihman B, et al. 2005. Lower brain‐derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. J Neuroimmunol 167: 215–218. [DOI] [PubMed] [Google Scholar]
  3. Banwell B, Reder AT, Krupp L, et al. 2006. Safety and tolerability of interferon β‐1b in pediatric multiple sclerosis. Neurology 66: 472–476. [DOI] [PubMed] [Google Scholar]
  4. Barkhof F, Filippi M, Miller DH, et al. 1997. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120: 2059–2069. [DOI] [PubMed] [Google Scholar]
  5. Barkhof F, Hommes O, Scheltens P, et al. 1991. Quantitative MRI changes in gadolinium‐DTPA enhancement after high‐dose intravenous methylprednisolone in multiple sclerosis. Neurology 41: 1219–1222. [DOI] [PubMed] [Google Scholar]
  6. Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55: 458–468. [DOI] [PubMed] [Google Scholar]
  7. Bechtold DA, Kapoor R, Smith KJ. 2004. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55: 607–616. [DOI] [PubMed] [Google Scholar]
  8. Beck RW. 1988. The Optic Neuritis Treatment Trial. Arch Ophthalmol 106: 1051–1053. [DOI] [PubMed] [Google Scholar]
  9. Beutler E, Sipe J, Romine JS, et al. 1996. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93: 1716–1720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Boiko A, Vorobeychik G, Paty D, et al. 2002. Early onset multiple sclerosis: A longitudinal study. Neurology 59: 1006–1010. [DOI] [PubMed] [Google Scholar]
  11. Bourdette DN, Edmonds E, Smith C, et al. 2005. A highly immunogenic trivalent T cell receptor peptide vaccine for MS. Mult Scler 11: 552–561. [DOI] [PubMed] [Google Scholar]
  12. Brass SD, Caramanos Z, Santos C. 2003. Multiple sclerosis and acute disseminated encephalomyelitis in childhood. Pediatr Neurol 29: 227–231. [DOI] [PubMed] [Google Scholar]
  13. Burnham JA, Wright RR, Dreisbach J, et al. 1991. The effect of high‐dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 41: 1349–1354. [DOI] [PubMed] [Google Scholar]
  14. Canadian Cooperative Multiple Sclerosis Study Group . 1991. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 441–446. [PubMed] [Google Scholar]
  15. Chataway J, Feakes R, Coraddu F. 1998. The genetics of multiple sclerosis: Principles, background and updated results of the United Kingdom systematic genome screen. Brain 121: 1869–1887. [DOI] [PubMed] [Google Scholar]
  16. Cohen O, Biran I, Steiner I. 2000. Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural CNS lesions. Arch Neurol 57: 553–557. [DOI] [PubMed] [Google Scholar]
  17. Cole GF, Auchterlonie LA, Best PV. 1995. Very early onset multiple sclerosis. Dev Med Child Neurol 37: 667–672. [DOI] [PubMed] [Google Scholar]
  18. Compston A. 2003. Genetic susceptibility and epidemiology In: Lazzarini RA, editor. Myelin Biology and Disorders. St. Louis, MO: Elsevier Academic; pp 701–731. [Google Scholar]
  19. Correale J, Lund B, McMillian M. 2000. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 107: 130–139. [DOI] [PubMed] [Google Scholar]
  20. Currier RD, Haerer AF, Meydrech EF. 1993. Low dose oral methotrexate treatment of multiple sclerosis: A pilot study. J Neurol Neurosurg Psychiatry 56: 1217–1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dale RC, de Sousa C, Chong WK, et al. 2000. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123: 2407–2422. [DOI] [PubMed] [Google Scholar]
  22. Duquette P, Murray TJ, Pleines J, et al. 1987. Multiple sclerosis in childhood: Clinical profile in 125 patients. Disabil Rehabil 111: 359–363. [DOI] [PubMed] [Google Scholar]
  23. Fazekas F, Deisenhammer F, Strasser‐Fuchs S, et al. 1997. Randomised placebo‐controlled trial of monthly intravenous immunoglobulin therapy in relapsing‐remitting multiple sclerosis. Lancet 349: 589–593. [DOI] [PubMed] [Google Scholar]
  24. Frohman EM, Racke MK, Raine CS. 2006. Multiple sclerosis—The plaque and its pathogenesis. N Engl J Med 354: 942–955. [DOI] [PubMed] [Google Scholar]
  25. Gadoth N. 2003. Multiple sclerosis in children. Brain Dev 25: 229–232. [DOI] [PubMed] [Google Scholar]
  26. Gall JC, Hayles AB, Siekert RG, et al. 1958. Multiple sclerosis in children: A clinical study of 40 cases with onset in childhood. Pediatrics 21: 703–709. [PubMed] [Google Scholar]
  27. Ghezzi A, Amato MP, Capobianco M, et al. 2005. Disease‐modifying drugs in childhood‐juvenile multiple sclerosis: Results of an Italian co‐operative study. Mult Scler 11: 420–424. [DOI] [PubMed] [Google Scholar]
  28. Goodin DS, Frohman EM, Garmany GP, et al. 2002. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58: 169–178. [DOI] [PubMed] [Google Scholar]
  29. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. 1995. Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37: 30–40. [DOI] [PubMed] [Google Scholar]
  30. Hahn CD, Shroff MM, Blaser SL, et al. 2004. MRI criteria for multiple sclerosis: Evaluation in a pediatric cohort. Neurology 62: 806–808. [DOI] [PubMed] [Google Scholar]
  31. Harris CJ, Halper J. 2004. Multiple Sclerosis: Best Practices in Nursing Care. Disease Management, Pharmacologic Treatment, Nursing Research, 2nd ed. New York: BioScience; p 19. [Google Scholar]
  32. Hauser SL, Dawson DM, Lehrich JR, et al. 1983. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three‐arm study of high‐dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308: 173–180. [DOI] [PubMed] [Google Scholar]
  33. Hynson JL, Kornberg AJ, Coleman LT. 2001. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 56: 1308–1312. [DOI] [PubMed] [Google Scholar]
  34. John GR, Shankar SL, Shafit‐Zagardo B, et al. 2002. Multiple sclerosis: Re‐expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 8: 1115–1121. [DOI] [PubMed] [Google Scholar]
  35. Johnson RT, Major E. 2003. Infectious demyelinating diseases In: Lazzarini RA, editor. Myelin Biology and Disorders. St. Louis, MO: Elsevier Academic; pp 953–983. [Google Scholar]
  36. Jones CT. 2003. Childhood autoimmune neurologic diseases of the CNS. Neurol Clin N Am 21: 745–764. [DOI] [PubMed] [Google Scholar]
  37. Kenealy SJ, Pericak‐Vance MA, Haines JL. 2003. The genetic epidemiology in MS. J Neuroimmunol 143: 7–12. [DOI] [PubMed] [Google Scholar]
  38. Kupersmith MJ, Kaufman D, Paty DW, et al. 1994. Megadose corticosteroids in multiple sclerosis. Neurology 44: 1–4. [DOI] [PubMed] [Google Scholar]
  39. Kurtzke JF. 1983. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444–1452. [DOI] [PubMed] [Google Scholar]
  40. Likosky W, Fireman B, Elmore R, et al. 1991. Intense immunosuppression in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 54: 1055–1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lo AC, Saab CY, Black JA, et al. 2003. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90: 3566–3571. [DOI] [PubMed] [Google Scholar]
  42. Lucchinetti CF, Bruck W, Parisi J, et al. 1999. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122: 2279–2295. [DOI] [PubMed] [Google Scholar]
  43. Lucchinetti CF, Bruck W, Parisi J, et al. 2000. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47: 707–717. [DOI] [PubMed] [Google Scholar]
  44. Lucchinetti CF, Bruck W, Rodriguez M, et al. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6: 259–274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Matute C, Pérez‐Cerdá F. 2005. Multiple sclerosis: Novel perspectives on newly forming lesions. Trends Neurosci 28: 173–175. [DOI] [PubMed] [Google Scholar]
  46. McDonald WI, Compston A, Edan G, et al. 2001. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50: 121–127. [DOI] [PubMed] [Google Scholar]
  47. Merrill JE. 1992. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and CNS acquired immunodeficiency syndrome. J Immunother 12: 167–170. [DOI] [PubMed] [Google Scholar]
  48. Mi S, Miller RH, Lee X, et al. 2005. LINGO‐1 negatively regulates myelination by oligodendrocytes. Nature Neurosci 8: 745–751. [DOI] [PubMed] [Google Scholar]
  49. Millefiorini E, Gasperini C, Pozzilli C, et al. 1997. Randomized placebo‐controlled trial of mitoxantrone in relapsing‐remitting multiple sclerosis: 24‐Month clinical and MRI outcome. J Neurol 244: 153–157. [DOI] [PubMed] [Google Scholar]
  50. Miller DH, Robb SA, Ormerod IE, et al. 1990. Magnetic resonance imaging of inflammatory and demyelinating white‐matter diseases of childhood. Dev Med Child Neurol 32: 97–107. [DOI] [PubMed] [Google Scholar]
  51. Moreau T, Coles A, Wing M, et al. 1996. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119: 225–237. [DOI] [PubMed] [Google Scholar]
  52. Neuhaus O, Farina C, Wekerle H, et al. 2001. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56: 702–708. [DOI] [PubMed] [Google Scholar]
  53. Neuhaus O, Strasser‐Fuchs S, Fazekas F, et al. 2002. Statins as immunomodulators: Comparison with interferon‐β1b in MS. Neurology 59: 970–971. [DOI] [PubMed] [Google Scholar]
  54. Neuhaus O, Stüve O, Zamviul S, et al. 2004. Are statins a treatment option for multiple sclerosis? Lancet Neurol 3: 369–371. [DOI] [PubMed] [Google Scholar]
  55. Oldstone MB. 1998. Molecular mimicry and immune‐mediated diseases. FASEB J 12: 1255–1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Olek MJ, Dawson DM. 2004. Multiple sclerosis and other inflammatory demyelinating diseases of the CNS In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in Clinical Practice: The Neurologic Disorders, 4th ed. Philadelphia, PA: Butterworth‐Heinemann; pp 1650–1651. [Google Scholar]
  57. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994; 36: S25–S28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Paolillo A, Coles AJ, Molyneux PD. 1999. Quantitative MRI in patients with secondary progressive multiple sclerosis treated with monoclonal antibody Campath 1H. Neurology 53: 751–757. [DOI] [PubMed] [Google Scholar]
  59. Polman CH, O'Connor PW, Havrdova E, et al. 2006. A randomized, placebo‐controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910. [DOI] [PubMed] [Google Scholar]
  60. Polman CH, Reingold SC, Edan G, et al. 2005. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 58: 840–846. [DOI] [PubMed] [Google Scholar]
  61. Poser C. 1983. The diagnosis In: Scheinberg LC, editor. Multiple Sclerosis: A Guide for Patients and Their Families. New York: Raven; p 31. [Google Scholar]
  62. Poser C. 1995. Onset symptoms in multiple sclerosis. J Neurol Neursurg Psychiatry 58: 253–254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Poser C, Paty D, Scheinberg L, et al. 1983. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13: 227–231. [DOI] [PubMed] [Google Scholar]
  64. Reff ME, Carner K, Chambers KS, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435–445. [PubMed] [Google Scholar]
  65. Rice G. 2004. The genetic epidemiology of multiple sclerosis In: Miller AE, editor. Continuum: Multiple Sclerosis. Philadelphia, PA: Lippincott; p 28. [Google Scholar]
  66. Rice G, Filippi M, Comi G. 2000. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Neurology 54: 1145–1155. [DOI] [PubMed] [Google Scholar]
  67. Robinson WH, Fontoura P, Lee BJ, et al. 2003. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 21: 1033–1039. [DOI] [PubMed] [Google Scholar]
  68. Ropper AH. 2006. Selective treatment of multiple sclerosis. N Engl J Med 354: 965–967. [DOI] [PubMed] [Google Scholar]
  69. Rose AS, Kuzma JW, Kurtzke JF, et al. 1970. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo—Final report. Neurology 209: 1–59. [DOI] [PubMed] [Google Scholar]
  70. Rudge P, Koetsier JC, Mertin J, et al. 1989. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 52: 559–565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Rudick R, Stuart W, Calabresi P, et al. 2006. Natalizumab plus interferon β‐1a for relapsing multiple sclerosis. N Engl J Med 354: 911–923. [DOI] [PubMed] [Google Scholar]
  72. Ruggieri M, Polizzi A, Pavone L, et al. 1999. Multiple sclerosis in children under 6 years of age. Neurology 53: 478–484. [DOI] [PubMed] [Google Scholar]
  73. Selcen D, Anlar B, Renda Y. 1996. Multiple sclerosis in childhood: Report of 16 cases. Eur Neurol 36: 79–84. [DOI] [PubMed] [Google Scholar]
  74. Sibley WA, Bamford CR, Clark K. 1985. Clinical viral infection and multiple sclerosis. Lancet 1: 1313–1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Sindern E, Haas J, Stark E, et al. 1992. Early onset MS under the age of 16: Clinical and paraclinical features. Acta Neurol Scand 86: 280–284. [DOI] [PubMed] [Google Scholar]
  76. Sorensen PS, Wanscher B, Jensen CV, et al. 1998. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50: 1273–1281. [DOI] [PubMed] [Google Scholar]
  77. Sorensen TL, Tani M, Jensen J, et al. 1999. Expression of specific chemokines and chemokine receptors in the CNS of multiple sclerosis patients. J Clin Invest 103: 807–815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Stonehouse M, Gupte G, Wassmer E, et al. 2003. Acute disseminated encephalomyelitis: Recognition in the hands of general paediatricians. Arch Dis Child 88: 122–124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Stüve O, Youssef S, Steinman L, et al. 2003. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16: 393–401. [DOI] [PubMed] [Google Scholar]
  80. Teitelbaum D, Milo R, Arnon R, et al. 1992. Synthetic copolymer 1 inhibits human T‐cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 89: 137–141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Thompson AJ, Kennard C, Swash M, et al. 1989. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 39: 969–971. [DOI] [PubMed] [Google Scholar]
  82. Tinoré M, Rovira A, Martinez MJ, et al. 2000. Isolated demyelinating syndromes: Comparison of different MR criteria to predict conversion to clinically‐definite multiple sclerosis. Am J Neuroradiol 21: 702–706. [PMC free article] [PubMed] [Google Scholar]
  83. Valentine MA, Meier KE, Rossie S, et al. 1989. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264: 11282–11287. [PubMed] [Google Scholar]
  84. Vasselon T, Detmers PA. 2002. Toll receptors: A central element in innate immune responses. Infect Immun 70: 1033–1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Vollmer T, Key L, Durkalski V, et al. 2004. Oral simvastatin treatment in relapsing–remitting multiple sclerosis. Lancet 363: 1607–1608. [DOI] [PubMed] [Google Scholar]
  86. Wang KC, Kim JA, Sivasankaran R, et al. 2002. P75 interacts with the Nogo receptor as a co‐receptor for Nogo, MAG and OMgp. Nature 420: 74–78. [DOI] [PubMed] [Google Scholar]
  87. Waubant E, Hietpas J, Stewart T, et al. 2001. Interferon β‐1a in children with multiple sclerosis is well tolerated. Neuropediatrics 32: 211–213. [DOI] [PubMed] [Google Scholar]
  88. Waxman SG, Craner MJ, Black JA. 2004. Na+ channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 25: 584–591. [DOI] [PubMed] [Google Scholar]
  89. Wechsler IS. 1922. Statistics of multiple sclerosis; including a study of the infantile, congenital, familial and hereditary forms and the mental and psychic symptoms. Arch Neurol Psychiatry 8: 59. [Google Scholar]
  90. Weiner HL, Mackin GA, Orav EJ, et al. 1993. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43: 910–918. [DOI] [PubMed] [Google Scholar]
  91. Weinshenker BG, O'Brien PC, Petterson TM, et al. 1999. A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease. Ann Neurol 46: 878–886. [DOI] [PubMed] [Google Scholar]
  92. Werner P, Pitt D, Raine CS. 2001. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50: 169–180. [DOI] [PubMed] [Google Scholar]
  93. Wolinsky JS, Narayana PA. 2002. Magnetic resonance spectroscopy in multiple sclerosis: Window into the diseased brain. Curr Opin Neurol 15: 247–251. [DOI] [PubMed] [Google Scholar]
  94. Youssef S, Stüve O, Patarroyo J, et al. 2002. The HMG‐CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature 420: 78–84. [DOI] [PubMed] [Google Scholar]
  95. Yudkin PL, Ellison GW, Ghezzi A, et al. 1991. Overview of azathioprine treatment in multiple sclerosis. Lancet 338: 1051–1055. [DOI] [PubMed] [Google Scholar]

Articles from Mental Retardation and Developmental Disabilities Research Reviews are provided here courtesy of Wiley

RESOURCES